Literature DB >> 10588296

A modification of Simon's optimal design for phase II trials when the criterion is median sample size.

J J Hanfelt1, R S Slack, E A Gehan.   

Abstract

We present a modification to Simon's optimal design for phase II trials in which the objective is to minimize the median sample size rather than the expected sample size when the true response rate is poor (p = p0). We argue that the modified design may be preferred in smaller institutions when the focus is on a single or small number of phase II trials rather than a large program of phase II trials.

Mesh:

Year:  1999        PMID: 10588296     DOI: 10.1016/s0197-2456(99)00028-8

Source DB:  PubMed          Journal:  Control Clin Trials        ISSN: 0197-2456


  10 in total

1.  Forewarning of hypotensive events using a Bayesian artificial neural network in neurocritical care.

Authors:  Rob Donald; Tim Howells; Ian Piper; P Enblad; P Nilsson; I Chambers; B Gregson; G Citerio; K Kiening; J Neumann; A Ragauskas; J Sahuquillo; R Sinnott; A Stell
Journal:  J Clin Monit Comput       Date:  2018-05-24       Impact factor: 2.502

2.  A Bayesian design for phase II clinical trials with delayed responses based on multiple imputation.

Authors:  Chunyan Cai; Suyu Liu; Ying Yuan
Journal:  Stat Med       Date:  2014-05-12       Impact factor: 2.373

3.  MIDAS: a practical Bayesian design for platform trials with molecularly targeted agents.

Authors:  Ying Yuan; Beibei Guo; Mark Munsell; Karen Lu; Amir Jazaeri
Journal:  Stat Med       Date:  2016-04-25       Impact factor: 2.373

4.  A two-stage phase II clinical trial design with nested criteria for early stopping and efficacy.

Authors:  Michelle DeVeaux; Michael Kane; Wei Wei; Daniel Zelterman
Journal:  Pharm Stat       Date:  2019-09-10       Impact factor: 1.894

5.  Spatial Two-stage Designs for Phase II Clinical Trials.

Authors:  Seongho Kim; Weng Kee Wong
Journal:  Comput Stat Data Anal       Date:  2022-01-06       Impact factor: 1.681

6.  Two-stage designs optimal under the alternative hypothesis for phase II cancer clinical trials.

Authors:  A P Mander; S G Thompson
Journal:  Contemp Clin Trials       Date:  2010-08-01       Impact factor: 2.226

7.  A Bayesian hierarchical monitoring design for phase II cancer clinical trials: Incorporating information on response duration into monitoring rules.

Authors:  Jian Wang; Junsheng Ma; Chunyan Cai; Naval Daver; Jing Ning
Journal:  Stat Med       Date:  2021-06-07       Impact factor: 2.497

8.  Phase II trial of short-term neoadjuvant docetaxel and complete androgen blockade in high-risk prostate cancer.

Authors:  B Mellado; A Font; A Alcaraz; L A Aparicio; F J G Veiga; J Areal; E Gallardo; N Hannaoui; J R M Lorenzo; A Sousa; P L Fernandez; P Gascon
Journal:  Br J Cancer       Date:  2009-09-15       Impact factor: 7.640

9.  Phase II study of temozolomide and veliparib combination therapy for sorafenib-refractory advanced hepatocellular carcinoma.

Authors:  Andrew Gabrielson; Anteneh A Tesfaye; John L Marshall; Michael J Pishvaian; Brandon Smaglo; Reena Jha; Karen Dorsch-Vogel; Hongkun Wang; Aiwu Ruth He
Journal:  Cancer Chemother Pharmacol       Date:  2015-10-08       Impact factor: 3.333

10.  Two-Stage Single-Arm Trials Are Rarely Analyzed Effectively or Reported Adequately.

Authors:  Michael J Grayling; Adrian P Mander
Journal:  JCO Precis Oncol       Date:  2021-12-16
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.